Jeannine Grebe, NP
Women's Health · Powell, TNNPI 1912016288
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Among women's health clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$837
- Mayne Pharma Commercial LLC$581
- Novo Nordisk$510
- Astellas Pharma US Inc$486
- Exeltis, USA Inc.$274
- Ascend Therapeutics US, LLC$248
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,00694%
- Education$2996%
- Gifts$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $837 |
| Mayne Pharma Commercial LLC | 29 | $581 |
| Novo Nordisk | 29 | $510 |
| Astellas Pharma US Inc | 14 | $486 |
| Exeltis, USA Inc. | 17 | $274 |
| Ascend Therapeutics US, LLC | 23 | $248 |
| Lilly USA, LLC | 11 | $243 |
| Therapeuticsmd, Inc. | 16 | $237 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $217 |
| Pfizer | 11 | $183 |
| Organon | 7 | $141 |
| Sumitomo Pharma America, Inc. | 7 | $136 |
| Corcept Therapeutics | 7 | $135 |
| Millicent US Inc | 6 | $131 |
| Hologic Sales And Service, LLC | 6 | $100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $90 |
| Avion Pharmaceuticals | 5 | $86 |
| Intra-sana Laboratories | 4 | $73 |
| Bausch Health US, LLC | 4 | $71 |
| Scynexis, Inc. | 4 | $70 |
| Bayer | 3 | $69 |
| Supernus Pharmaceuticals, Inc. | 4 | $69 |
| Myovant Sciences Inc. | 3 | $54 |
| Mycovia Pharmaceuticals, Inc. | 2 | $50 |
| Sage Therapeutics, LLC | 2 | $35 |
| Dysis Medical, Inc. | 1 | $22 |
| Boston Scientific | 1 | $22 |
| Lupin Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Agile Therapeutics, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIJUVA$125
- ZEPBOUND$122
- NURTEC ODT$119
How this compares
$5,314 in reported general payments places this provider in the 90th percentile of 202 women's health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 21 | $13,415 |
| Estradiol (Twice Weekly)Estradiol | 47 | $5,813 |
| Estradiol | 92 | $5,776 |
| PremarinEstrogens, Conjugated | 12 | $5,689 |
| ProgesteroneProgesterone, Micronized | 122 | $5,668 |
| DottiEstradiol | 34 | $4,273 |
| Clobetasol Propionate | 60 | $2,027 |
| ValacyclovirValacyclovir Hcl | 36 | $1,868 |
| LyllanaEstradiol | 15 | $1,309 |
| Spironolactone | 29 | $704 |
| Metronidazole | 11 | $413 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $339 |
| Nystatin | 27 | $327 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $301 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $486 | $13,41521 claims |
| PfizerPremarin | $183 | $5,68912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 202 women's health providers in Tennessee.
Other women's health in Powell
- Leslie StonePowell$2K
- Haley WoodFranklin$92K
- Dana DemossNashville$76K
- Royanne MooreNashville$29K
- Laurie TompkinsBrentwood$27K
- Lana HirschNashville$24K
- Yoshie DarnallNashville$10K
- Lisa GoehringNashville$9K
- Anya ZerillaKnoxville$8K
- Catherine KingeryKnoxville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.